Aegerion Pharmaceuticals (AEGR) may be up 200% YTD, but that doesn't mean the shares don't have...

|About: Aegerion Pharmaceuticals (AEGR)|By:, SA News Editor

Aegerion Pharmaceuticals (AEGR) may be up 200% YTD, but that doesn't mean the shares don't have more room to run, or so says Needham's Chad Messer who ups his price target to $100 from $50. "Assuming just 17% of [an] estimated 14K eligible patients are on treatment by 2018, we forecast worldwide Juxtapid sales of $590M, equating to AEGR EPS of $7.28," Messer notes. Slap a 30x multiple on that (which Messer justifies as "conservative" by referring to peers' multiples), apply a 25% discount, and you have yourself a $100 12-month PT.